United Therapeutics Company Profile and Analysis

United Therapeutics is a biotechnology company that has made significant contributions to the field of rare and orphan diseases. Founded in 1996 by Dr. Martine Rothblatt, the company has grown to become a leading developer of innovative therapies.

United Therapeutics is headquartered in Silver Spring, Maryland, and has a strong presence in the biotech industry. Its commitment to advancing treatments for complex diseases has earned it a reputation as a trusted partner in the medical community.

The company's focus on rare and orphan diseases has led to the development of several groundbreaking therapies, including Tyvaso for pulmonary arterial hypertension.

Suggestion: Bcbs Prime Therapeutics

United Therapeutics is a biotechnology company founded by Martine A. Rothblatt on June 26, 1996. It's headquartered in Silver Spring, MD.

The company has a diverse portfolio of products, including Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin, which are designed to treat patients with chronic and life-threatening conditions.

United Therapeutics is a large-cap company with a market capitalization of $19.60 billion, placing it in the large capitalization category.

Take a look at this: Jpmcb Large Cap Growth Fund

Our company has two main locations where you can find us. Our primary location is at 1000 Spring Street, Silver Spring, Maryland 20910, US.

If you're in the area, you can easily get directions to our primary location. We're also located in Research Triangle Park, North Carolina 27709, US.

Here are our two locations:

United Therapeutics Corp., also known as UTHR, is a biotechnology company that develops and commercializes products for patients with chronic and life-threatening conditions.

The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

UTHR's products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

UTHR has a large market capitalization, falling between $10 billion and $200 billion, placing it in the large capitalization category.

Worth a look: Scalable Creative Solutions Large Businesses

United Therapeutics Corporation has a strong financial foundation, with a Chief Financial Officer and Treasurer, James Edgemond, at the helm.

The company reported a significant revenue growth of 12% year-over-year in Q2 2025, reaching $799 million.

United Therapeutics' $1 billion accelerated share repurchase program provides a buffer against near-term volatility, thanks to its robust cash flow of $1.2 billion in the first half of 2025.

The company's annual revenue was $2.8 billion in 2025, demonstrating a substantial financial presence.

A September data readout could potentially catalyze a re-rating of the stock, particularly if TETON 2 meets its primary endpoints.

United Therapeutics has a strong leadership team, with Rev. Dr. Christopher J. Edwards serving as the company's President and Chief Executive Officer since 2003. He has led the company's growth and expansion into new areas.

The company's board of directors includes experienced professionals like Dr. Martine Rothblatt, who has a background in medicine and law. This diverse skillset brings a unique perspective to the company's decision-making process.

United Therapeutics has a strong commitment to governance, with a focus on transparency and accountability. The company has implemented various measures to ensure compliance with regulatory requirements.

Under Dr. Edwards' leadership, the company has made significant investments in research and development, driving innovation and growth. This focus on R&D has enabled the company to develop new treatments and expand its product portfolio.

For your interest: How to Build a Strong Brand Identity

United Therapeutics operates in a competitive industry. The company's competitors are found in the Health Technology sector and Pharmaceuticals: Major group.

United Therapeutics has a large market capitalization, falling within the $10 billion to $200 billion range. This categorizes the company as a large capitalization entity.

The IPF market is highly competitive, with several players vying for market share.

Explore further: Large Value Transfer System

United Therapeutics embodies Peter Lynch's GARP strategy, which stands for "Growth At a Reasonable Price." A 50% estimated trial success rate suggests the company's growth potential is substantial, making it a prime candidate for this strategy.

This success rate is particularly noteworthy given the significant market opportunity of $7.15 billion.

See what others are reading: Etsy Success Stories

United Therapeutics is making significant strides in the clinical trial space, particularly with its TETON 1 and TETON 2 trials.

The TETON 1 trial has completed its primary safety review and is on track to report results in September, with 598 patients enrolled in February 2025. The trial's primary endpoint is a clinically meaningful measure for IPF, a disease characterized by progressive lung function decline.

Consider reading: Virtual Debit Card for Free Trial

The data monitoring committee's unanimous recommendation to continue the trial without modification underscores the safety profile of nebulized treprostinil, a key consideration for regulatory approval. This is a testament to the company's commitment to patient safety.

The TETON 2 trial has also reached completion, with data expected in September. This trial aims to establish nebulized treprostinil as a first-line treatment for IPF, a market currently underserved by therapies that address both pulmonary arterial hypertension and fibrosis.

The open-label extension study, which began in 2022, further strengthens the long-term safety narrative, a critical factor for chronic disease management. This study will provide valuable insights into the safety and efficacy of nebulized treprostinil over an extended period.

You might like: Docusign Free Trial Limitations

Despite a recent earnings miss, the stock remains undervalued relative to analyst projections.

The IPF market is projected to grow significantly, from $3.5 billion in 2025 to $7.15 billion by 2035. This growth is driven by advancements in drug delivery and disease prevalence. The stock's current valuation doesn't accurately reflect this potential for growth.

Analysts think United Therapeutics' stock is undervalued, despite a recent earnings miss.

The IPF market is projected to grow from $3.5 billion in 2025 to $7.15 billion by 2035, driven by advancements in drug delivery and disease prevalence.

This growth is expected to be driven by a rise in disease prevalence and advancements in drug delivery.

The company's nebulized treprostinil is well-positioned to capture a meaningful share of this growth due to its non-invasive administration and dual mechanism of action.

You might enjoy: Meyer Brothers Drug Company

Corporations are often misunderstood, but they're actually a type of business ownership that can provide significant benefits.

In the United States, corporations are created through a process called incorporation, which involves filing articles of incorporation with the state government. This process typically requires a minimum amount of capital and a board of directors.

One of the key advantages of corporations is their ability to issue stock, which can be bought and sold on public markets. This allows corporations to raise capital from a large number of investors.

Corporations are also often used to protect the personal assets of their owners, known as shareholders, from business debts and liabilities. This is because corporations are considered separate entities from their owners.

Discover more: Foreign Companies Often Offshore Their Manufacturing Here

United Therapeutics Corporation has a SIC code of 28, 283.

The company's SIC codes provide a clear classification of its industry and operations.

United Therapeutics Corporation's SIC code of 28 indicates that it operates in the chemical and allied products sector.

This classification helps investors, researchers, and industry analysts understand the company's business model and market position.

United Therapeutics Corporation's SIC code of 283 specifically indicates that it operates in the pharmaceutical preparation manufacturing industry.

Explore further: Bank Sic Code